Oncology Medical Communications
& Pharma Marketing India.

The regulatory framework for oncology medical communications

Oncology medical communications in India operates against the most demanding regulatory framework of any therapeutic area. The CDSCO's New Drug and Clinical Trials Rules 2019 (NDCT 2019) governs investigational oncology product communications. ICMR ethical guidelines for biomedical research apply to all oncology trial documentation. Schedule Y of the Drugs and Cosmetics Rules governs post-approval safety reporting cycles. The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 explicitly prohibits cancer-cure claims in promotional materials — a constraint that shapes every line of oncology brand communications.

The UCPMP 2024 promotional-content framework is the day-to-day operating constraint. Comparative claims between oncology products are permissible only with head-to-head trial data — no cross-trial comparisons. Survival data (overall survival, progression-free survival) must be reported with the exact endpoint definitions, censoring rules, and hazard ratios as published — paraphrasing is a UCPMP violation. Adverse event grading must follow CTCAE (Common Terminology Criteria for Adverse Events) without simplification. ICG's oncology engagements have an internal pre-MLR review that scores every content piece against these criteria before external review.

The evidence architecture — what makes oncology different

Oncology HCPs evaluate efficacy on three primary endpoints: Overall Survival (OS) — the gold standard but often unavailable for early-line therapies; Progression-Free Survival (PFS) — the workhorse endpoint with debated clinical relevance; and Objective Response Rate (ORR) — useful for accelerated approval but rarely sufficient for full approval. ICG's oncology medical writing teams are trained to present each endpoint with its specific clinical interpretation — what the number means, what its limits are, and how it relates to the patient's lived experience.

Safety analysis in oncology requires CTCAE-graded adverse event tables, immune-related adverse event (irAE) reporting for immuno-oncology products, and dose-modification analysis for tolerability assessment. ICG's safety analytics integrate with Pharos Vigil to surface AE patterns within minutes — a capability that becomes critical when responding to KOL queries during congresses or advisory boards.

The audience — and why precision matters

Oncology HCPs in India are among the most statistically literate clinical audiences. Many have advanced fellowships from Tata Memorial Centre, AIIMS, or international centres (MD Anderson, Memorial Sloan Kettering, Royal Marsden). They read primary literature continuously. They are sceptical of cross-trial comparisons. They expect precision in trial design discussion. ICG's oncology engagements are calibrated for this audience — and rejected by it the moment imprecision appears. The discipline pays dividends: KOLs who trust the content recommend the brand more often than KOLs who don't.

Outcome targets

(1) Publication acceptance in oncology journals — JCO, Annals of Oncology, Lancet Oncology, Cancer, and high-impact specialty journals. (2) KOL engagement quality — measurable via paired KOL surveys at 12 months. (3) PSUR / DSUR inspection-readiness — 100% on-time submissions with zero quality-system findings. (4) Brand commercial impact — prescriber-share lift measurable via Pharos RxFlow.